In the past years, novel treatment choices for alopecia areata (AA) have emerged, including the Janus Kinase (JAK) inhibitors. “Unfortunately, trials slowed down due to the pandemic, and all 3 approved JAK inhibitors –ruxolitinib, tofacitinib, and baricitinib– have no indication for AA,” said Prof. Natasha Mesinkovska (UC Irvine School of Medicine, CA, USA). Based on currently available data, one can expect response rates of 46–75%. The agents are well tolerated but expensive. “Long-term use is needed; when the medication is discontinued, hair falls out again,” said Prof. Mesinkovska. In addition, AA is a chronic condition, and sometimes after an initial response, hair still falls out despite continued JAK inhibitor treatment. Although the agents have been associated with a risk of herpes zoster, the risk is small.
JAK inhibitors have also demonstrated to be effective in children and adolescents with hair loss and in alopecia universalis. Even in patients who did not have any hair for years, regrowth has been observed. Unfortunately, about one-third of patients do not respond to treatment. Whether higher doses or longer treatment periods might be justified in these patients remains unclear. Other options currently under investigation are dupilumab, apremilast, and ustekinumab. The selective sphingosine-1-phosphate (S1P) receptor modulator etrasimod may be an interesting novel different pathway in AA.
Allergies contribute to AA
Allergies seem to play a role in AA. In a histopathology study, an eosinophilic infiltrate around the hair bulbs of AA patients was detected in 30.8% of cases in the acute stage but only in 7.7% in the chronic stage [2]. A higher risk of allergic disease such as rhinitis, asthma, and atopic dermatitis (AD) has been reported in AA. One study found that AA patients had higher IgE concentrations, and dust mite allergy against was associated with early-onset AA and severe AA [3]. Mast cells were also found in histologic samples of AA patients. Patients with AA have a 2.6 time increased risk for AD. “We all notice a seasonal pattern in AA with more flares in spring and late autumn,” Prof. Mesinkovska said. These flares coincide with flare frequencies of patients with AD. “This is the rationale to try antihistamines in AA,” Prof. Mesinkovska suggested. Antihistamines such as fexofenadine might be able to enhance hair regrowth. According to Prof. Mesinkovska, their use should be considered in the high-risk seasons: autumn and spring.
A potential novel treatment option for AA patients may be the IL-4/13 antagonist dupilumab. However, the role of this biologic is controversial: some patients with new-onset alopecia had hair regrowth after they were treated with dupilumab for their AD but other patients developed AA after having been treated with dupilumab for their AD.
Scalp allergic contact dermatitis: another cause of alopecia
Many hair products can potentially cause scalp allergic contact dermatitis (ACD). Typical symptoms are erythema (25%), pruritus or itching (22%), and scale (10%). Of note, only 9.3% of patients suffer from scalp dermatitis solely. In most cases, signs can be found elsewhere on the body, including neck, face, and forehead. A review demonstrated that hair dye (most frequently phenylenediamine) is responsible for most ACD cases (48%), another 27% are caused by shampoo, and 8% by topical minoxidil. Alopecia develops in about 10% of ACD cases. To detect the culprit, a full history of allergies, a body exam, and a diagnostic biopsy are warranted. In addition, a patch test should be performed.
Frontal fibrosing alopecia (FFA) is a chronic cicatricial alopecia with unknown aetiology and a rising incidence worldwide. In previous years, a controversy arose about a possible correlation between facial sunscreen use and development of frontal fibrosing alopecia. A study found a high use of sunscreens in women with FFA [4]. A Brazilian case-control study in a multiracial population found a positive association between FFA and the use of moisturisers, facial soap, and hair straightening with formalin, and a negative association with the use of anti-residue/clarifying shampoo. The authors concluded that their study reinforces the possibility of an exogenous particle triggering FFA [5].
- Mesinkovska N. HOT Topics: Alopecia. Session S027, AAD VMX 2021, 23-25 April.
- Yoon TY, et al. JAMA Dermatology 2014;150(9):952-6.
- Li SF, et al. Clin Exp Dermatol 2015;40(2):171-6.
- Aldoori N, et al. Br J Dermatol 2016;175(4):762-7.
- Ramos PM, et al. J Am Acad Dermatol 2021;84(3):712-8.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« ATS 2021 Highlights Podcast Next Article
Non-invasive tests may enable some patients with NAFLD avoid biopsy »
« ATS 2021 Highlights Podcast Next Article
Non-invasive tests may enable some patients with NAFLD avoid biopsy »
Table of Contents: AAD 2021
Featured articles
Letter from the Editor
Late-Breaking Abstracts
Small molecule effective in moderate-to-severe psoriasis
Bruton’s tyrosine kinase inhibition promising for pemphigus vulgaris
Bimekizumab superior to secukinumab in psoriasis
Etrasimod – a new mode of action for treatment of atopic dermatitis
Women at higher risk for dermatologic side effects during immunotherapy
Novel easy-to-use foam formulation clears scalp psoriasis in one-third of patients
Anti-cholinergic gel demonstrates superior long-term tolerability and efficacy in axillary hyperhidrosis
Psoriasis – The Beat Goes On
Psoriasis: The treatment armamentarium continues to grow
Psoriasis management in times of COVID-19: the knowledge is growing steadily
Lower burden of high-risk atherosclerotic plaques in psoriasis patients treated with biologics
COVID-19: What Dermatologists Need to Know
Psoriasis and hidradenitis suppurativa during COVID-19: keep calm and carry on
COVID-19 in children – cutaneous involvement is common
Cutaneous reactions after COVID-19 vaccination: an update
Novel Developments in Sun Protection
Sunless tanning and other developments in sun protection
What Is Hot in Atopic Dermatitis
Comorbidity is common in adult and paediatric atopic dermatitis patients
Significant improvements in the system armamentarium for AD treatment
Topical pan-JAK inhibitor cream safe and efficacious in atopic dermatitis
Hairy Matters – What Is New in Alopecia
Allergies: an underrated factor in alopecia pathogenesis
Botulinum toxin A: a contradictory role in hair loss
Platelet-rich plasma in androgenetic alopecia – hype or hope?
Acne – New Developments
New therapeutic options add value to current acne treatment
Nicotinamide and probiotics can support acne therapy
Pearls of the Posters
Related Articles
September 29, 2021
Live varicella-zoster vaccine safe, effective with TNF inhibitors
July 31, 2023
PsA patients: highest risk of developing NAFLD
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com